Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal recessive primary immunodeficiency characterized by recurrent bacterial infections associated with agammaglobulinemia and absence of circulating B cells. Additional features include failure to thrive and skin involvement. The severity is variable: more severe cases may require hematopoietic stem cell transplantation, whereas others can be treated effectively with Ig replacement therapy.
Features include always present findings: Agammaglobulinemia, Recurrent bacterial infections, and Absent circulating B cells; and common findings: Failure to thrive, Eczematoid dermatitis, and Low platelet count (thrombocytopenia). 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 2 | Seborrheic dermatitis, Eczematoid dermatitis |
SLC39A7 function has not been fully characterized.
Agammaglobulinemia 9, autosomal recessive is associated with mutations in the SLC39A7 gene on chromosome 6.
Genetic testing for SLC39A7 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for agammaglobulinemia 9, autosomal recessive has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 3 common features.
No clinical trials have been registered for agammaglobulinemia 9, autosomal recessive.
6 publications have been identified in PubMed for agammaglobulinemia 9, autosomal recessive. Research spans Case Report / Case Series (50%), Epidemiology / Natural History (33%), and Diagnostic / Biomarker (17%).
Hlongwa L (2026). [PMID: 41692833](https://pubmed.ncbi.nlm.nih.gov/41692833/). *Sci Rep*. [Epidemiology / Natural History]
Boyarchuk O (2025). [PMID: 40443574](https://pubmed.ncbi.nlm.nih.gov/40443574/). *Frontiers in pediatrics*. [Case Report / Case Series]
Lee JK (2025). [PMID: 41275043](https://pubmed.ncbi.nlm.nih.gov/41275043/). *Journal of clinical immunology*. [Diagnostic / Biomarker]
Abd Elhamed MM (2025). [PMID: 41022419](https://pubmed.ncbi.nlm.nih.gov/41022419/). *BMJ case reports*. [Case Report / Case Series]
Özdemiral C (2025). [PMID: 40862510](https://pubmed.ncbi.nlm.nih.gov/40862510/). *Journal of medical virology*. [Epidemiology / Natural History]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
Online Mendelian Inheritance in Man
Common questions about agammaglobulinemia 9, autosomal recessive
Blood and immune system |
2 |
Recurrent bacterial infections, Low platelet count (thrombocytopenia) |
Growth and development | 1 | Failure to thrive |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Almutairy KA (2024). [PMID: 39439639](https://pubmed.ncbi.nlm.nih.gov/39439639/). *Cureus*. [Case Report / Case Series]